Asensus Surgical, Inc.

Rampartab, Chief Financial Officer. Before we begin, I would like to caution listeners that certain information discussed by management during this conference call, including any guidance provided, are forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the company's business, including any geopolitical risk factors beyond our control. The company undertakes no obligation to update the information provided on this call. For a discussion of risks and uncertainties associated with the Ascensus Surgical business, I encourage you to review the company's filings with the Securities and Exchange Commission including the 2022 Form 10-K filed in March 2023 and the Form 10-Q expected to be filed later today and any other filings we make with the SEC. During this call, we will also present certain non-GAAP financial information related to adjusted net loss attributable to common stockholders and the adjusted net loss per share attributable to common stockholders. Management believes that these non-GAAP financial measures taken in conjunction with U.S. GAAP financial measures provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company's core operating results. Management uses non-GAAP financial measures to compare our performance relative to forecast and strategic plans, to benchmark outperformance externally against competitors, and for certain compensation decisions. Reconciliations from US GAAP to non-GAAP results are presented in the tables accompanying our earnings release, which can be found in the investor relations section of our website. With that, it's my pleasure to turn the call over to a Census Surgical's President and Chief Executive Officer, Anthony Fernando.

Thanks, Mark, and thank you everyone for joining us today. To kick off, I'll provide an overview of our recent performance and key achievements after which Shamice will detail our financial results. Next, I'll update you on our priorities for the rest of 2023 before we open the line for questions. During the second quarter, we made good progress across all our key areas. Our focus remains on expanding the adoption of Senhance, driving broader utilization of our Intelligent Surgical Unit, or ISU, advancing our clinical body of evidence, and refining our portfolio to further enhance the capability of SENHAS. Looking ahead, we are excited about the future with plans in place for the development of our new lunar surgical system. Procedure volumes remain a key factor in our ability to expand and optimize our digital surgery capabilities. As we continue to collect surgical data, our machine learning engine becomes more effective allowing us to provide valuable clinical intelligence to surgeons through the ISU. During the second quarter, we continued to see robust positive trends, delivering 27% year-over-year growth and over 11% sequencer growth, with over 1,000 enhanced procedures performed across a variety of specialties globally. Over the past quarter, we have maintained a consistent 10% sequential growth rate, reflecting our commitment to progress and stability. Another positive aspect of increased procedure volumes is the expansion of our clinical registry. Our trust registry now includes data from over 2,500 patients with a growing number of cases across gynecology, general surgery, and neurology, which has been aided by the continued expansion of sites participating in the registry. The primary goal for this registry is to create a collection of intraoperative and 12-month postoperative follow-up data. This data will be used to support and increase number of quality clinical publications and contribute to our market development strategy. Moving to new program initiations. We initiated two new SENHANCE programs year-to-date. The first was Fukuoka Tokushikai Hospital in Kasuga City, which we highlighted in our previous earnings call. In Japan, our growth continues as we enter into agreements with prominent institutions. We are pleased with the positive momentum in the country and are looking forward to supporting further adoption in the region. The second is a leading U.S. hospital that has initiated the Senhance program exclusively within their pediatric surgery department, highlighting Senhance's unique suitability for pediatric applications. This marks an important milestone as this is the first system to be exclusively utilized by pediatric surgeons at a U.S.-based hospital. We continue to be active at key industry meetings to generate excitement about Senhance, the ISU, and ultimately, Luna. In July, we participated in the Society of Robotic Surgery, or SRS, annual meeting held in Melbourne, Australia. SRS is a unique event where all robotic surgical technologies from various specialties come together. During the event, we had several podium presentations and symposiums featuring both company representatives and surgeons providing an excellent opportunity to showcase the unique capabilities of Sennheil, Luna, and the ISU. The substantial interest and engagement we received regarding ISU and Luna were particularly encouraging, and our presence at this event signifies our commitment to driving innovation in robotics and digital surgery. Additionally, we attended the first joint meeting of the International Pediatric Endosurgery Group, or IPEC, and the European Society of Pediatric Endoscopic Surgeons, or ESPERS, meeting. We hosted a number of key events, including our sponsored ESPERS robotic masterclass, which allowed surgeons from around the globe to explore robotics in pediatric surgery. The masterclass received positive feedback and our hands-on training sessions showcase the precision and efficiency of the SennHands system in pediatric procedures. After attending several of these conferences over the past few quarters, we've seen strong validation of SennHands' potential amidst the influx of new systems planning to be on the market. Our understanding of market needs backed by real-world experience and valuable user input sets us apart. The unique offering of real-time augmented intelligence has generated excitement from surgeons and hospital administrators alike, and we are confident we hold an edge over future market entrants. Turning to other recent developments, as we stated earlier, during the quarter, we made progress in expanding our presence in the pediatric Since having received FDA clearance in March 2023, we have seen strong interest from pediatric surgeons. Our efforts to develop pediatric-specific real-world data have shown promising results, demonstrating the safety and feasibility of using Senhance in pediatric cases. The combination of Senhance's features, such as 3-millimeter instrumentation and haptic feedback, along with the ISU's clinical intelligence, makes it highly effective for pediatric procedures. We have obtained the necessary clearances and approvals, including CE mark and FDA 510K clearance, allowing us to support surgeons globally and improve outcomes. We continue to see increased interest in Senhans and the ISU for pediatrics, and are committed to meeting the growing demand in the market. In conclusion, I'm happy with the progress we've made in the second quarter and our strategic positioning for long-term success. Now, I will hand over the call to Shamiz, who will provide a financial update.

Thanks, Anthony. Turning to the second quarter, for the three months ended June 30th, 2023, The company reported revenue of $1.1 million as compared to revenue of $1 million in the three months ended June 30th, 2022. Revenue in the second quarter of 2023 included $0.5 million in lease revenue, $0.3 million in instruments and accessories, and $0.3 million in services. For the three months ended June 30th, 2023, total operating expenses were $18.9 million as compared to $18.2 million in the three months ended June 30th, 2022. For the three months ended June 30th, 2023, net loss attributable to common stockholders was $20.7 million or 9 cents per share as compared to a net loss attributable to common stockholders of $19.6 million or $0.08 per share in the three months ended June 30, 2022. For the three months ended June 30, 2023, the adjusted net loss attributable to common stockholders was $20.3 million, or $0.09 per share, as compared to an adjusted net loss of $17.3 million, or $0.07 per share, in the three months ended June 30, 2022. Adjusted net loss is GAAP net loss adjusted for the following items. amortization of intangible assets, change in fair value of contingent consideration, and impairment of property and equipment, all of which are non-cash charges. Adjusted net loss attributable to common stockholders is a non-GAAP financial measure. Reconciliation from GAAP to non-GAAP measures can be found in our earnings release. Turning to the balance sheet. The company had cash, cash equivalents, and short-term investments, excluding restricted cash, of approximately $40 million as of June 30, 2023. In July, subsequent to the end of the second quarter, we completed a registered direct offering, bringing in gross proceeds of approximately $10 million. We plan to allocate these funds to reinforce our working capital and contribute to research and development. Based on the recent financing, and our current operating plan, we project our cash runway has been extended through late second quarter of 2024. I'll turn the call back over to Anthony.